STUDIES OF DRUG-ELUTING INTRACORONARY STENTS


  1. 77 patients with symptomatic CAD and a single coronary lesion (maximum length, 15 mm) randomized to intracoronary stenting with a standard stent vs. one bonded with paclitaxel.  Loss of luminal diameter at 6mos was sig. lower in paclitaxel group (NEJM 348:1537, 2003--JW)
  2. In a randomized trial in 1058 pts randomized to sirolimus-eluting stenting vs. standard metal stents, 9mo incidence of (cardiac death, MI, or repeat target-lesion revascularization) was sig. lower in sirolimus-eluting group (7% vs. 19%) (NEJM 349:1315, 2003--JW)
  3. In a randomized trial in 352 pts randomized to sirolimus-eluting stenting vs. standard metal stents, 9mo incidence of major adverse cardiac events was sig. lower in sirolimus group (8% vs. 23%) ("E-SIRIUS" study; Lancet 362:1093, 2003--JW)
  4. 1326 pts with single-vessel CAD randomized to paclitaxel-eluting intracoronary stent vs. bare-metel stent.  9mo incidence of restenosis was sig. lower in paclitaxel group (5% vs. 12%) ("TAXUS-IV" trial; NEJM 350:221, 2004--JW)
  5. In a study of 42 pts with coronary stenosis randomized to stenting with an everolimus-eluting stent vs. a bare metal stent; at 6mos, the restenosis rate was nonsig. lower in the everolimus-eluting stent group (0% vs. 9.1%)("FUTURE I" trial; Circ. 109:2168, 2004--abst)
  6. In a randomized trial in 257 pts undergoing PTCA for small (2.75mm or less) stenosed arteries, sirolimus-coated stents vs. standard stents were ass'd with sig. lower 8-month incidence of restenosis (9.8% vs. 53.1%) and major adverse cardiac events (9.3% vs. 31.3%) ("SES-SMART" trial; JAMA 292:2727, 2004--abst)